Withdrawal of chronic systemic corticosteroids in patients with COPD: A randomized trial

Kathryn L. Rice, Jeffrey B. Rubins, Fran Lebahn, Connie M. Parenti, Peter G. Duane, Michael Kuskowski, Anne M. Joseph, Dennis E. Niewoehner

Research output: Contribution to journalArticlepeer-review

77 Scopus citations


The benefits of chronic systemic corticosteroids for patients with chronic obstructive pulmonary disease (COPD) are not well established. To determine whether chronic corticosteroid treatment can be safely withdrawn in 'steroid-dependent' COPD patients, we performed a double-blind, placebo- controlled study of 38 patients with steroid-dependent COPD. Patients were randomly assigned to receive their usual maintenance prednisone dose for 6 mo (continuous group) or to be withdrawn from prednisone at a rate of 5 mg per week (demand group). The number of COPD exacerbations per patient (primary outcome) was 2.5 ± 2.7 (mean ± SD) in the continuous group and 2.7 ± 2.5 in the demand group (p = 0.60, 95% confidence interval for the difference: - 1.1 to 1.7). Spirometric results, dyspnea, and health-related quality of life did not differ significantly in the two groups. The average daily corticosteroid dose was 10.7 ± 5.2 mg in the continuous group and 6.3 ± 6.4 mg in the demand group (p = 0.003). Weight decreased in the demand group by 4.8 ± 2.0 kg, compared with an increase in the continuous group of 0.5 ± 3.5 kg (p = 0.007). Discontinuation of chronic systemic corticosteroid treatment in steroid-dependent COPD patients did not cause a significant increase in COPD exacerbations, but did reduce total systemic corticosteroid use and body weight. Larger studies may be warranted to establish the relative risks and benefits of chronic corticosteroid treatment of patients with COPD.

Original languageEnglish (US)
Pages (from-to)174-178
Number of pages5
JournalAmerican journal of respiratory and critical care medicine
Issue number1
StatePublished - 2000


Dive into the research topics of 'Withdrawal of chronic systemic corticosteroids in patients with COPD: A randomized trial'. Together they form a unique fingerprint.

Cite this